通过激活PI3K/AKT通路,E2F3/CDCA2可以降低胃腺癌中的放射敏感性
Jun Gao1, Huaqiao Wang1, Xiujuan Qiu2
1Department of General Surgery, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang, China.
The British journal of radiology
|September 26, 2023
概括
E2F3/CDCA2轴促进胃腺癌的进展,并通过激活PI3K/AKT通路来减少辐射敏感性. 这个轴代表了这种日益增长的全球癌症的潜在新治疗目标.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 胃腺癌是癌症死亡的主要原因之一,发病率不断上升.
- 核蛋白CDCA2与促进瘤生长有关.
研究的目的:
- 研究CDCA2在胃腺癌进展和放射敏感性中的作用.
- 阐明涉及CDCA2.2的潜在分子机制.
主要方法:
- 生物信息分析以确定差异表达的基因和上游调节者.
- 定量实时PCR (qRT-PCR) 和分子实验以验证监管关系.
- 细胞活力 (CCK-8),增殖和辐射敏感性测定 (殖民地形成),以及PI3K/AKT通路的西部斑点分析.
主要成果:
- 在胃腺癌中,CDCA2被显著上调,促进了增殖和降低了辐射敏感性.
- PI3K/AKT通路抑制剂逆转了CDCA2对增殖和辐射敏感性的影响.
- E2F3被确定为一种上游转录因子,激活CDCA2,通过PI3K/AKT通路驱动增殖并降低辐射敏感性.
结论:
- E2F3/CDCA2轴促进胃腺癌细胞的增殖,并降低辐射敏感性.
- 这个轴通过激活PI3K/AKT通路来运行.
- E2F3/CDCA2轴为胃腺癌提供了一个新的治疗点.
相关概念视频
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Electron Transport Chain: Complex I and II
14.3K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
14.3K


